Abstract: The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of Bifidobacterium, Bacteroides fragilis group, Lactobacillus brevis, and Lactobacillus plantarum subgroup and/or the total number of intestinal bacteria as a marker, and a method for determining Parkinson's disease using the blood LPS level and/or the blood LBP level of a Parkinson's disease patient as an indicator.

Abstract: An easily polymerizable substance handling device is provided that can prevent generation of irregularities and steps between a pipeline and a cover member due to the cover member being installed at an opening part of the pipeline. A cover part 3 is formed to have a curved surface 3a on a side closer to inside of a pipeline 1. The shape of the surface 3a on the pipeline 1 side is preferably a concave shape when viewed from inside of the pipeline 1. The shape of the surface 3a of the cover part 3 on the pipeline 1 side is more preferably the shape of a curved surface having a curvature radius equal or approximate to that of the internal circumference of the pipeline 1. With this configuration, a polymer material is unlikely to be generated at the cover part 3 and around a gap 1b at an opening part 1a, and the frequency of cleaning can be reduced as compared to conventional cases.

Abstract: The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of Bifidobacterium, Bacteroides fragilis group, Lactobacillus brevis, and Lactobacillus plantarum subgroup and/or the total number of intestinal bacteria as a marker, and a method for determining Parkinson's disease using the blood LPS level and/or the blood LBP level of a Parkinson's disease patient as an indicator.

Abstract: Disclosed herein is a method for determining whether a test subject has equol-producing ability or not. The method involves measuring equol-producing ability of a test subject, wherein an equol converting enzyme gene derived from enteric bacteria of the test subject is detected using three types of primer sets described herein as the primer sets a) to c).

Abstract: An object of the present invention is to provide a method of quantitating or detecting a microorganism, capable of detecting a live microorganism at high sensitivity and more precisely. A method of quantitating a microorganism of interest, using as an index the amount of rRNA of the microorganism of interest is provided.

Abstract: Disclosed herein is a method for determining whether a test subject has equol-producing ability or not. The method involves measuring equol-producing ability of a test subject, wherein an equol converting enzyme gene derived from enteric bacteria of the test subject is detected using three types of primer sets described herein as the primer sets a) to c).

Abstract: An agent for the prevention and treatment of chlamydia infection containing Lactobacillus casei as an active ingredient which is an agent for the prevention and treatment of chlamydia infection that is highly safe and that can be administered over an extended period of time.

Abstract: An object of the invention is to provide a medical drug, a food and drink having a role in regulating the concentration of equol in vivo and being capable of taking for a long time with high safety and provide a selective medium for a microorganism having conversion ability to equol and a method of detecting the same. Provided are an equol concentration-raising or reducing agent containing a carbohydrate as an active ingredient; use of a carbohydrate for producing the equol concentration-raising or reducing agent; a method of raising or reducing the concentration of equol by administrating a carbohydrate in an effective dose; a selective medium containing a carbohydrate for a microorganism having conversion ability to equol; and a method of detecting a microorganism having conversion ability to equol by use of the selective medium.

Abstract: The present invention is directed to a microorganism having an ability of converting daidzein to equol in 24 hours of 50% or higher; a food/beverage or pharmaceutical composition containing the microorganism; an equol production method employing the microorganism; and a nucleic acid fragment which can specifically detect the microorganism.

Abstract: The present invention is directed to a microorganism having an ability of converting daidzein to equol in 24 hours of 50% or higher; a food/beverage or pharmaceutical composition containing the microorganism; an equol production method employing the microorganism; and a nucleic acid fragment which can specifically detect the microorganism.

Abstract: An object of the invention is to provide a medical drug, a food and drink having a role in regulating the concentration of equal in vivo and being capable of taking for a long time with high safety and provide a selective medium for a microorganism having conversion ability to equal and a method of detecting the same. Provided are an equal concentration-raising or reducing agent containing a carbohydrate as an active ingredient; use of a carbohydrate for producing the equal concentration-raising or reducing agent; a method of raising or reducing the concentration of equal by administrating a carbohydrate in an effective dose; a selective medium containing a carbohydrate for a microorganism having conversion ability to equal; and a method of detecting a microorganism having conversion ability to equal by use of the selective medium.

Abstract: An object of the present invention is to provide a method of quantitating or detecting a microorganism, capable of detecting a live microorganism at high sensitivity and more precisely. A method of quantitating a microorganism of interest, using as an index the amount of rRNA of the microorganism of interest is provided.

Abstract: An antitumor agent is provided by including, as an active ingredient, a polysaccharide-glycan complex obtained by treating a Gram-positive bacteria such as lactic acid bacteria and Bifidobacterium strains with a cell wall lytic enzyme produced by a bacterium belonging to the genus Achromobacter.The polysaccharide-glycan complex has no toxicity and causes no side effect. Being water-soluble, it is easily formulated into any arbitrary dose form, such as an injectable solution. It can easily be prepared from an easily available starting material.